U.S. Biosensors Market Size To Reach $15.61 Billion By 2030

U.S. Biosensors Market Growth & Trends

The U.S. biosensors market size is anticipated to reach USD 15.61 billion by 2030 and is projected to grow at a CAGR of 7.13% from 2024 to 2030, according to a new report by Grand View Research, Inc. It encompasses various biosensor devices, components, technologies, and services used across multiple industries, such as healthcare, food safety, environmental monitoring, agriculture, biotechnology, and security.

The U.S. market is experiencing significant growth driven by a combination of factors. One key driver is the increasing demand for point-of-care testing (POCT) solutions, which offer rapid and convenient diagnostic capabilities outside of traditional laboratory settings.

Biosensors play a crucial role in diagnosing, monitoring, and managing these conditions, driving demand for innovative biosensor solutions. Regulatory support and approvals for biosensor technologies and a growing emphasis on personalized medicine are also contributing to market expansion. For instance, the FoundationOne CDx test, approved by the FDA, is a companion diagnostic utilizing next-generation sequencing to detect advanced cancer patients who could potentially benefit from targeted therapies. The test uses biosensors to examine tumor DNA to provide details on actionable genomic alterations.

 Request a free sample copy or view report summary: U.S. Biosensors Market Report

U.S. Biosensors Market Report Highlights

• Based on technology, the electrochemical segment led the market with the largest revenue share of 72.86% in 2023, due to its diverse use across various sectors and industries, these biosensors can be miniaturized and integrated into portable devices such as personal glucose meter that provides fast measurement of blood glucose levels for personal glycemic management

• Based on application, the medical segment led the market with the largest revenue share of 65.57%in 2023, due to the rapid and accurate diagnostic tools, emphasis on personalized medicine, advancements in healthcare technology, and others. For instance, in November 2021, Quanterix, a U.S.-based company specializing in digital biomarker solutions, announced the release of its Simoa Ultra-Sensitive Biosensors Platform. This platform empowers the detection of low-abundance biomarkers associated with various diseases

• Based on end-use, the point of care (PoC) testing segment led the market with the largest revenue share of 47.67% in 2023, due to their demand in various settings including clinics, pharmacies, and emergency departments

U.S. Biosensors Market Segmentation

Grand View Research has segmented the U.S. biosensors market report based on technology, application, end-use, and region:

U.S. Biosensors Technology Outlook (Revenue, USD Million, 2018 - 2030)

• Thermal

• Electrochemical

• Piezoelectric

• Optical

U.S. Biosensors Application Outlook (Revenue, USD Million, 2018 - 2030)

• Medical

  • Cholesterol

  • Blood Glucose

  • Pregnancy Test

  • Drug Discovery

  • Infectious Disease

• Food Toxicity

• Bioreactor

• Agriculture

• Environment

• Others

U.S. Biosensors End-use Outlook (Revenue, USD Million, 2018 - 2030)

• Home Healthcare Diagnostics

• PoC Testing

• Food Industry

• Research Laboratories

• Security and Bio-defence

U.S. Biosensors Regional Outlook (Revenue, USD Million, 2018 - 2030)

• West

• Midwest

• Northeast

• Southwest

• Southeast

List of Key Players in the U.S. Biosensors Market

• Abbott

• Medtronic

• F. Hoffmann-La Roche Ltd

• Dexcom, Inc.

• SENTINEL

• Intricon Corporation

• Quanterix

• Koninklijke Philips N.V.

• Masimo

• Siemens Healthcare Private Limited

• Molecular Devices, LLC.

• Johnson & Johnson Services, Inc.

• Thermo Fisher Scientific Inc.

• PerkinElmer Inc.

• Covaris, LLC